ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3%
Tue, 21 Aug

ASTRAZENECA PHARMA has announced its results for the quarter ended June 2018. Here is a detailed performance review of the same:

ASTRAZENECA PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-17*
3
Mar-18*
3
Jun-18*
QoQ ChangeYoY Change
Net SalesRs m1,2851,5071,6147.1%25.7%
Other incomeRs m47233446.4%-26.5%
TurnoverRs m1,3311,5311,6497.7%23.8%
ExpensesRs m1,2221,3551,52212.3%24.5%
Gross profitRs m6215393-39.2%49.3%
DepreciationRs m3736360.0%-4.3%
InterestRs m0000.0%0.0%
Profit before taxRs m7214192-34.9%27.8%
TaxRs m1410828-74.5%102.0%
Profit after taxRs m58326498.4%10.3%
Gross profit margin%4.810.15.7
Effective tax rate%19.177.130.1
Net profit margin%4.42.13.9
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 25.7% on a year-on-year (YoY) basis. The expenses were up by 24.5% YoY during the same period.
  • The company's operating profit increased by 49.3% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 5.7% in 1QFY19 as against 4.8% in 1QFY18.
  • Depreciation charges and finance costs declined by 4.3% YoY and 0.0% YoY, respectively.
  • Other income declined by 26.5% YoY during the quarter.
  • Net profit for the quarter increased by 10.3% YoY. Net profit margins during the quarter declined from 4.4% in 1QFY18 to 3.9% in 1QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 7.1% on a quarter-on-quarter (QoQ) basis. The expenses were up by 12.3% QoQ during the same period.
  • The company's operating profit declined by 39.2% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 5.7% in 1QFY19 as against 10.1% in 4QFY18.
  • Net profit for the quarter increased by 98.4% QoQ, while net profit margins increased from 2.1% in 4QFY18 to 3.9% in 1QFY19.

To see how ASTRAZENECA PHARMA has performed over the last eight quarters, please visit here.

ASTRAZENECA PHARMA Share Price Performance

Over the last one year, ASTRAZENECA PHARMA share price has moved up from Rs 898.5 to Rs 1,814.0, registering a Gain of Rs 915.6 or around 101.9%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 15,319.2 (up 1.2%). Over the last one year it has moved up from 12,730.1 to 15,319.2, a gain of 2,589 points (up 20.3%).

Overall, the S&P BSE SENSEX is up 22.5% over the year.

Current Valuations

At the current price of Rs 1,814.0, the price to earnings (P/E) ratio of ASTRAZENECA PHARMA stands at 170.2 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 26.4 times.

Equitymaster requests your view! Post a comment on "ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3%". Click here!

  

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Bet on These Smallcap Stocks for Success in 2020(Profit Hunter)

Jan 14, 2020

The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.

Guess Which Stocks Are Rising at Double the Speed of Sensex(Profit Hunter)

Jan 15, 2020

These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.

How to Buy the Best Safe Stocks in 2020(The 5 Minute Wrapup)

Jan 17, 2020

Don't fall for the safe stocks narrative going around in the stock market these days.

For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market(Fast Profits Daily)

Jan 17, 2020

This is how the biggest trading profits are made.

What the Infosys Results Tell Us About the Next Infosys(The 5 Minute Wrapup)

Jan 15, 2020

If you're interested in the next Infosys, I'll tell you where to look.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 24, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS